Compare Incyte Corporation (INCY) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Schwab US Large Cap Growth ETF — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 2.8× Incyte Corporation's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| INCY | SCHG | |
|---|---|---|
Market Cap | $22.85B | $65.01B |
Volume | 1,927,029 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $36.93 |
52-Week Low | $83.80 | $28.10 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SCHG trades at $36.72, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's role in growth portfolios and tax-efficient strategies, with Seeking Alpha noting its valuation discount compared to QQQM as of September 9, 2026.
SCHG offers exposure to large-cap growth stocks with competitive fees, though concentration in top holdings presents both opportunity and risk. The ETF's performance is closely tied to megacap technology names, making it sensitive to sector rotations. Long-term growth potential remains supported by historical outperformance, but investors should monitor holding concentration and market leadership shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
